DekaBank Deutsche Girozentrale Decreases Position in Regeneron Pharmaceuticals, Inc. $REGN

DekaBank Deutsche Girozentrale decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 211,207 shares of the biopharmaceutical company’s stock after selling 9,969 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Regeneron Pharmaceuticals were worth $110,009,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. E Fund Management Hong Kong Co. Ltd. grew its stake in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management grew its stake in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $27,000. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $27,000. Finally, Colonial Trust Advisors acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. Citigroup upped their price objective on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Finally, Truist Financial cut their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $817.88.

Regeneron Pharmaceuticals Stock Down 0.2%

Shares of Regeneron Pharmaceuticals stock opened at $576.77 on Tuesday. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The business’s 50 day simple moving average is $575.25 and its 200-day simple moving average is $562.14. The stock has a market capitalization of $61.13 billion, a price-to-earnings ratio of 14.54, a PEG ratio of 1.80 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $991.23.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $11.56 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.